Appropriate clinical use of darunavir 800 mg
No abstract available.
Main Authors: | Michelle A. Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2018-10-01
|
Series: | Southern African Journal of HIV Medicine |
Online Access: | https://sajhivmed.org.za/index.php/hivmed/article/view/918 |
Similar Items
-
Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
by: Michelle A. Moorhouse, et al.
Published: (2018-10-01) -
Paraquat poisoning: Acute lung injury – a missed diagnosis
by: Sipho D Ntshalintshali, et al.
Published: (2017-05-01) -
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01) -
The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances
by: S. A. Zolotov, et al.
Published: (2021-02-01) -
Desensitization to darunavir in a pediatric patient
by: Julio César Cambray-Gutiérrez, et al.
Published: (2015-07-01)